"The U.S. Food and Drug Administration today notified Ranbaxy Laboratories, Ltd., that it is prohibited from manufacturing and distributing active pharmaceutical ingredients (APIs) from its facility in Toansa, India, for FDA-regulated drug product"...
Overdosage with QUADRAMET® (samarium sm 153 lexidronam) has not been reported. An antidote for QUADRAMET® (samarium sm 153 lexidronam) overdosage is not known. The anticipated complications of overdosage would likely be secondary to bone marrow suppression from the radioactivity of 153Sm, or secondary to hypocalcemia and cardiac arrhythmias related to the EDTMP.
QUADRAMET® (samarium sm 153 lexidronam) is contraindicated in patients who have known hypersensitivity to EDTMP or similar phosphonate compounds.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 10/8/2008
Additional Quadramet Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.